Targeting mutant p53 for efficient cancer therapy

The Protein Data Bank

Berman, H. M. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.1.235 · Cited by 40,196 · see citing works

The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data

Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455 · see citing works

p53 Mutations in Human Cancers

Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018 · see citing works

Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours

Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649 · see citing works

Mutational landscape and significance across 12 major cancer types

Kandoth, C., McLellan, M. D., Vandin, F., Ye, K., Niu, B., Lu, C., Xie, M., Zhang, Q., McMichael, J. F., Wyczalkowski, M. A., et al. (2013) · Nature · doi:10.1038/nature12634 · Cited by 4,419 · see citing works

Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms

Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765 · see citing works

Update on Key Emerging Challenges in Cystic Fibrosis

Jennings, M. T., Riekert, K. A., & Boyle, M. (2014) · Medical Principles and Practice · doi:10.1159/000357646 · Cited by 3,667 · see citing works

Modulation of oxidative stress as an anticancer strategy

Gorrini, C., Harris, I. S., & Mak, T. W. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4002 · Cited by 3,579 · see citing works

Ferroptosis as a p53-mediated activity during tumour suppression

Jiang, L., Kon, N., Li, T., Wang, S.-J., Su, T., Hibshoosh, H., Baer, R., & Gu, W. (2015) · Nature · doi:10.1038/nature14344 · Cited by 3,398 · see citing works

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients

Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380 · see citing works

Blinded by the Light: The Growing Complexity of p53

Vousden, K. H., & Prives, C. (2009) · Cell · doi:10.1016/j.cell.2009.04.037 · Cited by 3,163 · see citing works

DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis

Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688 · see citing works

Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations

Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P. (1994) · Science · doi:10.1126/science.8023157 · Cited by 2,559 · see citing works

Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas

Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473 · see citing works

Monitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift Assay

Molina, D. M., Jafari, R., Ignatushchenko, M., Seki, T., Larsson, E. A., Dan, C., Sreekumar, L., Cao, Y., & Nordlund, P. (2013) · Science · doi:10.1126/science.1233606 · Cited by 2,261 · see citing works

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., McArthur, G. A., Hutson, T. E., Moschos, S. J., Flaherty, K. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112302 · Cited by 2,156 · see citing works

Glutaminolysis and transferrin regulate ferroptosis

Gao, M., Monian, P., Quadri, N., Ramasamy, R., & Jiang, X. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.06.011 · Cited by 2,069 · see citing works

Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions

Gorgoulis, V. G., Vassiliou, L.-V. F., Karakaidos, P., Zacharatos, P., Kotsinas, A., Liloglou, T., Venere, M., DiTullio, R. A., Kastrinakis, N. G., Levy, B., et al. (2005) · Nature · doi:10.1038/nature03485 · Cited by 2,009 · see citing works

Putting p53 in context

Kastenhuber, E. R., & Lowe, S. W. (2017) · Cell · doi:10.1016/j.cell.2017.08.028 · Cited by 1,906 · see citing works

An Oncogene-Induced DNA Damage Model for Cancer Development

Halazonetis, T. D., Gorgoulis, V. G., & Bartek, J. (2008) · Science · doi:10.1126/science.1140735 · Cited by 1,851 · see citing works

Restoration of p53 function leads to tumour regression in vivo

Ventura, A., Kirsch, D. G., McLaughlin, M. E., Tuveson, D. A., Grimm, J., Lintault, L., Newman, J., Reczek, E. E., Weissleder, R., & Jacks, T. (2007) · Nature · doi:10.1038/nature05541 · Cited by 1,820 · see citing works

Mutant p53 in Cancer: New Functions and Therapeutic Opportunities

Muller, P. A. J., & Vousden, K. H. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.021 · Cited by 1,545 · see citing works

p53 mutant mice that display early ageing-associated phenotypes

Tyner, S. D., Venkatachalam, S., Choi, J., Jones, S., Ghebranious, N., Igelmann, H., Lu, X., Soron, G., Cooper, B., Brayton, C., et al. (2002) · Nature · doi:10.1038/415045a · Cited by 1,459 · see citing works

Unravelling mechanisms of p53-mediated tumour suppression

Bieging-Rolett, K. T., Mello, S. S., & Attardi, L. D. (2014) · Nature reviews. Cancer · doi:10.1038/nrc3711 · Cited by 1,389 · see citing works

Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome

Olive, K. P., Tuveson, D. A., Ruhe, Z. C., Yin, B., Willis, N. A., Bronson, R. T., Crowley, D., & Jacks, T. (2004) · Cell · doi:10.1016/j.cell.2004.11.004 · Cited by 1,308 · see citing works

Mechanism of protein stabilization by glycerol: preferential hydration in glycerol-water mixtures

Gekko, K., & Timasheff, S. N. (1981) · Biochemistry · doi:10.1021/bi00519a023 · Cited by 1,189 · see citing works

PTC124 targets genetic disorders caused by nonsense mutations

Welch, E. M., Barton, E. R., Zhuo, J., Tomizawa, Y., Friesen, W. J., Trifillis, P., Paushkin, S. V., Patel, M., Trotta, C. R., Hwang, S., et al. (2007) · Nature · doi:10.1038/nature05756 · Cited by 1,138 · see citing works

When mutants gain new powers: News from the mutant p53 field

Brosh, R., & Rotter, V. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2693 · Cited by 1,132 · see citing works

Aminoglycosides: Activity and Resistance

Mingeot‐Leclercq, M., Glupczynski, Y., & Tulkens, P. M. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.4.727 · Cited by 1,105 · see citing works

Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome

Lang, G. A., Iwakuma, T., Suh, Y.-A., Liu, G., Rao, V. A., Parant, J. M., Valentin-Vega, Y. A., Terzian, T., Caldwell, L. C., Strong, L. C., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.006 · Cited by 1,069 · see citing works

Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound

Bykov, V. J. N., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G., & Selivanova, G. (2002) · Nature Medicine · doi:10.1038/nm0302-282 · Cited by 1,067 · see citing works

RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors

Su, F., Virós, A., Milagre, C. S., Trunzer, K., Bollag, G. E., Spleiss, O., Reis-Filho, J. S., Kong, X., Koya, R. C., Flaherty, K. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105358 · Cited by 1,038 · see citing works

Tumor Suppression in the Absence of p53-Mediated Cell-Cycle Arrest, Apoptosis, and Senescence

Li, T., Kon, N., Jiang, L., Tan, M., Ludwig, T., Zhao, Y., Baer, R., & Gu, W. (2012) · Cell · doi:10.1016/j.cell.2012.04.026 · Cited by 912 · see citing works

Regulation of the specific DNA binding function of p53

Hupp, T. R., Meek, D. W., Midgley, C., & Lane, D. P. (1992) · Cell · doi:10.1016/0092-8674(92)90562-q · Cited by 905 · see citing works

Nonsense-mediated mRNA decay: an intricate machinery that shapes transcriptomes

Lykke‐Andersen, S., & Jensen, T. H. (2015) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm4063 · Cited by 843 · see citing works

Pharmacological Rescue of Mutant p53 Conformation and Function

Foster, B. A., Coffey, H. A., Morin, M. J., & Rastinejad, F. (1999) · Science · doi:10.1126/science.286.5449.2507 · Cited by 802 · see citing works

Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53

Michalovitz, D., Halevy, O., & Oren, M. (1990) · Cell · doi:10.1016/0092-8674(90)90113-s · Cited by 769 · see citing works

Aminoglycosides: Nephrotoxicity

Mingeot‐Leclercq, M., & Tulkens, P. M. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.5.1003 · Cited by 759 · see citing works

<i>TP53</i>Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data: Human Mutation

Bouaoun, L., Sonkin, D., Ardin, M., Hollstein, M., Byrnes, G., Zavadil, J., & Olivier, M. (2016) · Human Mutation · doi:10.1002/humu.23035 · Cited by 730 · see citing works

Drugging the p53 pathway: understanding the route to clinical efficacy

Khoo, K. H., Verma, C. S., & Lane, D. P. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4236 · Cited by 723 · see citing works

Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species

Suzuki, S., Tanaka, T., Poyurovsky, M. V., Nagano, H., Mayama, T., Ohkubo, S., Lokshin, M., Hosokawa, H., Nakayama, T., Suzuki, Y., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1002459107 · Cited by 705 · see citing works

Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer

Morton, J. P., Timpson, P., Karim, S. A., Ridgway, R. A., Athineos, D., Doyle, B., Jamieson, N. B., Oien, K. A., Lowy, A. M., Brunton, V. G., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908428107 · Cited by 657 · see citing works

Modeling the Therapeutic Efficacy of p53 Restoration in Tumors

Martins, C. P., Brown-Swigart, L., & Evan, G. I. (2006) · Cell · doi:10.1016/j.cell.2006.12.007 · Cited by 600 · see citing works

PRIMA-1 reactivates mutant p53 by covalent binding to the core domain

Lambert, J. M. R., Gorzov, P., Veprintsev, D. B., Söderqvist, M., Segerbäck, D., Bergman, J., Fersht, A. R., Hainaut, P., Wiman, K. G., & Bykov, V. J. N. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.003 · Cited by 592 · see citing works

PTEN Loss Confers BRAF Inhibitor Resistance to Melanoma Cells through the Suppression of BIM Expression

Paraiso, K. H. T., Xiang, Y., Rebecca, V. W., Abel, E. V., Chen, Y. A., Munko, A. C., Wood, E. R., Smalley, I., Sondak, V. K., Anderson, A. R. A., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2954 · Cited by 545 · see citing works

Gain of function of mutant p53 by coaggregation with multiple tumor suppressors

Xu, J., Reumers, J., Couceiro, J. R., De Smet, F., Gallardo, R., Rudyak, S., Cornelis, A., Rozenski, J., Zwolinska, A., Marine, J.-C., et al. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.546 · Cited by 543 · see citing works

Mechanism and regulation of the nonsense-mediated decay pathway

Hug, N., Longman, D., & Cáceres, J. F. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw010 · Cited by 535 · see citing works

A faux 3′-UTR promotes aberrant termination and triggers nonsense- mediated mRNA decay

Amrani, N., Ganesan, R., Kervestin, S., Mangus, D. A., Ghosh, S., & Jacobson, A. (2004) · Nature · doi:10.1038/nature03060 · Cited by 533 · see citing works

Distinct p53 Transcriptional Programs Dictate Acute DNA-Damage Responses and Tumor Suppression

Brady, C. A., Jiang, D., Mello, S. S., Johnson, T. M., Jarvis, L. A., Kozak, M. M., Broz, D. K., Basak, S., Park, E. J., McLaughlin, M. E., et al. (2011) · Cell · doi:10.1016/j.cell.2011.03.035 · Cited by 533 · see citing works

Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

McDonald, C. M., Campbell, C., Torricelli, R. E., Finkel, R. S., Flanigan, K. M., Goemans, N., Heydemann, P. T., Kamińska, A., Kirschner, J., Francesco Muntoni, A., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31611-2 · Cited by 451 · see citing works

Metabolic Regulation by p53 Family Members

Berkers, C. R., Maddocks, O. D. K., Cheung, E. C., Mor, I., & Vousden, K. H. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.06.019 · Cited by 443 · see citing works

Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy

Bullock, A. N., Henckel, J., & Fersht, A. R. (2000) · Oncogene · doi:10.1038/sj.onc.1203434 · Cited by 435 · see citing works

Small peptides activate the latent sequence-specific DNA binding function of p53

Hupp, T. R., Sparks, A., & Lane, D. P. (1995) · Cell · doi:10.1016/0092-8674(95)90165-5 · Cited by 433 · see citing works

TP53 Mutations in Human Cancer: Database Reassessment and Prospects for the Next Decade

Leroy, B., Anderson, M., & Soussi, T. (2014) · Human Mutation · doi:10.1002/humu.22552 · Cited by 412 · see citing works

Structural Basis of DNA Recognition by p53 Tetramers

Kitayner, M., Rozenberg, H., Kessler, N., Rabinovich, D., Shaulov, L., Haran, T. E., & Shakked, Z. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.05.015 · Cited by 408 · see citing works

Targeting p53 in Vivo: A First-in-Human Study With p53-Targeting Compound APR-246 in Refractory Hematologic Malignancies and Prostate Cancer

Lehmann, S., Bykov, V. J. N., Ali, D., Andrén, O., Cherif, H., Tidefelt, U., Uggla, B., Yachnin, J., Juliusson, G., Moshfegh, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.7783 · Cited by 406 · see citing works

Aminoglycoside antibiotics mediate context-dependent suppression of termination codons in a mammalian translation system

Manuvakhova, M., Keeling, K. M., & Bedwell, D. M. (2000) · RNA · doi:10.1017/s1355838200000716 · Cited by 404 · see citing works

Targeted rescue of a destabilized mutant of p53 by an in silico screened drug

Boeckler, F. M., Joerger, A. C., Jaggi, G., Rutherford, T. J., Veprintsev, D. B., & Fersht, A. R. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805326105 · Cited by 389 · see citing works

Shaping Genetic Alterations in Human Cancer: The p53 Mutation Paradigm

Soussi, T., & Wiman, K. G. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.10.001 · Cited by 366 · see citing works

Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma

Trunzer, K., Pavlick, A. C., Schuchter, L. M., Gonzalez, R. C., McArthur, G. A., Hutson, T. E., Moschos, S. J., Flaherty, K. T., Kim, K. B., Weber, J. S., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.7888 · Cited by 366 · see citing works

The inherent instability of mutant p53 is alleviated by Mdm2 or p16 INK4a lossPreprint

Terzian, T., Suh, Y., Iwakuma, T., Post, S. M., Neumann, M., Lang, G. A., Pelt, C. S. V., & Lozano, G. (2008) · Genes & Development · doi:10.1101/gad.1662908 · Cited by 356 · see citing works

An African-specific polymorphism in the TP53 gene impairs p53 tumor suppressor function in a mouse modelPreprint

Jennis, M., Kung, C.-P., Basu, S., Budina-Kolomets, A., Leu, J. I.-J., Khaku, S., Scott, J. P., Cai, K. Q., Campbell, M. R., Porter, D. K., et al. (2016) · Genes & Development · doi:10.1101/gad.275891.115 · Cited by 355 · see citing works

Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment

Alexandrova, E. M., Yallowitz, A. R., Li, D., Xu, S., Schulz‐Heddergott, R., Proia, D. A., Lozano, G., Dobbelstein, M., & Moll, U. M. (2015) · Nature · doi:10.1038/nature14430 · Cited by 354 · see citing works

Structural basis for understanding oncogenic p53 mutations and designing rescue drugs

Joerger, A. C., Ang, H. C., & Fersht, A. R. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607286103 · Cited by 354 · see citing works

Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain

Selivanova, G., Iotsova, V., Okan, İ., Fritsche, M., Ström, M., Groner, B., Grafström, R. C., & Wiman, K. G. (1997) · Nature Medicine · doi:10.1038/nm0697-632 · Cited by 343 · see citing works

A Designed Inhibitor of p53 Aggregation Rescues p53 Tumor Suppression in Ovarian Carcinomas

Soragni, A., Janzen, D. M., Johnson, L. M., Lindgren, A. G., Thai-Quynh Nguyen, A., Tiourin, E., Soriaga, A. B., Lu, J., Jiang, L., Faull, K. F., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2015.12.002 · Cited by 341 · see citing works

Inhibiting the system xC−/glutathione axis selectively targets cancers with mutant-p53 accumulation

Liu, D. S., Duong, C. P., Haupt, S., Montgomery, K. G., House, C. M., Azar, W. J., Pearson, H. B., Fisher, O. M., Read, M., Guerra, G. R., et al. (2017) · Nature Communications · doi:10.1038/ncomms14844 · Cited by 321 · see citing works

Allele-Specific p53 Mutant Reactivation

Yu, X., Vázquez, A., Levine, A. J., & Carpizo, D. R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.03.042 · Cited by 320 · see citing works

TP53: an oncogene in disguise

Soussi, T., & Wiman, K. G. (2015) · Cell Death &amp; Differentiation · doi:10.1038/cdd.2015.53 · Cited by 305 · see citing works

The glutamate/cystine xCT antiporter antagonizes glutamine metabolism and reduces nutrient flexibility

Shin, C.-S., Mishra, P., Watrous, J. D., Carelli, V., D’Aurelio, M., Jain, M., & Chan, D. C. (2017) · Nature Communications · doi:10.1038/ncomms15074 · Cited by 305 · see citing works

p53 Efficiently Suppresses Tumor Development in the Complete Absence of Its Cell-Cycle Inhibitory and Proapoptotic Effectors p21, Puma, and Noxa

Valente, L. J., Gray, D. H. D., Michalak, E. M., Hofbauer, J. P., Egle, A., Scott, C. L., Janic, A., & Strasser, A. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.04.012 · Cited by 292 · see citing works

A peptide that binds and stabilizes p53 core domain: Chaperone strategy for rescue of oncogenic mutants

Friedler, A., Hansson, L. O., Veprintsev, D. B., Freund, S. M. V., Rippin, T. M., Nikolova, P. V., Proctor, M. R., Rüdiger, S., & Fersht, A. R. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.241629998 · Cited by 268 · see citing works

PRIMA-1MET synergizes with cisplatin to induce tumor cell apoptosis

Bykov, V. J. N., Zache, N., Stridh, H., Westman, J., Bergman, J., Selivanova, G., & Wiman, K. G. (2005) · Oncogene · doi:10.1038/sj.onc.1208419 · Cited by 252 · see citing works

Reactivation of Mutant p53 and Induction of Apoptosis in Human Tumor Cells by Maleimide Analogs

Bykov, V. J. N., Issaeva, N., Zache, N., Shilov, A., Hultcrantz, M., Bergman, J., Selivanova, G., & Wiman, K. G. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501664200 · Cited by 247 · see citing works

Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancer

Walerych, D., Lisek, K., Sommaggio, R., Piazza, S., Ciani, Y., Dalla, E., Rajkowska, K., Gaweda-Walerych, K., Ingallina, E., Tonelli, C., et al. (2016) · Nature Cell Biology · doi:10.1038/ncb3380 · Cited by 239 · see citing works

Small molecule induced reactivation of mutant p53 in cancer cells

Liu, X., Wilcken, R., Joerger, A. C., Chuckowree, I., Amin, J., Spencer, J., & Fersht, A. R. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt305 · Cited by 235 · see citing works

Computational identification of a transiently open L1/S3 pocket for reactivation of mutant p53

Wassman, C. D., Baronio, R., Demir, Ö., Wallentine, B. D., Chen, C.-K., Hall, L., Salehi, F., Lin, D., Chung, B. P., Hatfield, G. W., et al. (2013) · Nature Communications · doi:10.1038/ncomms2361 · Cited by 222 · see citing works

The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML

Zhou, J., Bi, C., Cheong, L.-L., Mahara, S., Liu, S.-C., Tay, K.-G., Koh, T.-L., Yu, Q., & Chng, W. J. (2011) · Blood · doi:10.1182/blood-2010-07-294827 · Cited by 216 · see citing works

ASPP: a new family of oncogenes and tumour suppressor genes

Sullivan, A., & Lü, X. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603525 · Cited by 215 · see citing works

Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathway

Kravchenko, J. E., Ilyinskaya, G. V., Komarov, P. G., Agapova, L. S., Кочетков, Д. В., Strom, E., Frolova, E. I., Kovriga, I. E., Gudkov, A. V., Feinstein, E., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802091105 · Cited by 191 · see citing works

Activation of the cryptic DNA binding function of mutant forms of p53

Hupp, T. R., Meek, D. W., Midgley, C., & Lane, D. P. (1993) · Nucleic Acids Research · doi:10.1093/nar/21.14.3167 · Cited by 189 · see citing works

Characterization of the p53-rescue drug CP-31398 in vitro and in living cells

Rippin, T. M., Bykov, V. J. N., Freund, S. M. V., Selivanova, G., Wiman, K. G., & Fersht, A. R. (2002) · Oncogene · doi:10.1038/sj.onc.1205362 · Cited by 186 · see citing works

APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells

Mohell, N., Alfredsson, J., Fransson, Å., Uustalu, M., Byström, S., Gullbo, J., Hallberg, A., Bykov, V. J. N., Björklund, U., & Wiman, K. G. (2015) · Cell Death &amp; Disease · doi:10.1038/cddis.2015.143 · Cited by 183 · see citing works

Mutant p53 reactivation by small molecules makes its way to the clinic

Bykov, V. J. N., & Wiman, K. G. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.04.017 · Cited by 180 · see citing works

Correcting temperature-sensitive protein folding defects

Brown, C. R., Hong-Brown, L. Q., & Welch, W. J. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119302 · Cited by 176 · see citing works

Mechanism of rescue of common p53 cancer mutations by second‐site suppressor mutations

Nikolova, P. V., Wong, K., DeDecker, B. S., Henckel, J., & Fersht, A. R. (2000) · The EMBO Journal · doi:10.1093/emboj/19.3.370 · Cited by 173 · see citing works

Molecular basis for the high-affinity binding and stabilization of firefly luciferase by PTC124

Auld, D. S., Lovell, S., Thorne, N., Lea, W., Maloney, D. J., Shen, M., Rai, G., Battaile, K. P., Thomas, C. J., Simeonov, A. M., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909141107 · Cited by 173 · see citing works

Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database

Bykov, V. J. N. (2002) · Carcinogenesis · doi:10.1093/carcin/23.12.2011 · Cited by 172 · see citing works

APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase

Peng, X., Zhang, M.-Q.-Z., Conserva, F., Hosny, G., Selivanova, G., Bykov, V. J. N., Arnér, E. S. J., & Wiman, K. G. (2013) · Cell Death &amp; Disease · doi:10.1038/cddis.2013.417 · Cited by 170 · see citing works

Conservation of the Keap1-Nrf2 System: An Evolutionary Journey through Stressful Space and Time

Fuse, Y., & Kobayashi, M. (2017) · Molecules · doi:10.3390/molecules22030436 · Cited by 168 · see citing works

Identification and Characterization of Small Molecules That Inhibit Nonsense-Mediated RNA Decay and Suppress Nonsense p53 Mutations

Martin, L., Grigoryan, A., Wang, D., Wang, J., Breda, L., Rivella, S., Cardozo, T. J., & Gardner, L. B. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2235 · Cited by 167 · see citing works

PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance

Tessoulin, B., Descamps, G., Moreau, P., Maïga, S., Lodé, L., Godon, C., Marionneau-Lambot, S., Oullier, T., Le Gouill, S., Amiot, M., et al. (2014) · Blood · doi:10.1182/blood-2014-01-548800 · Cited by 166 · see citing works

Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations

Brachmann, R. K., Yu, K., Eby, Y. J., Pavletich, N. P., & Boeke, J. D. (1998) · The EMBO Journal · doi:10.1093/emboj/17.7.1847 · Cited by 156 · see citing works

Identification of a core TP53 transcriptional program with highly distributed tumor suppressive activityPreprint

Andrysík, Z., Galbraith, M. D., Guarnieri, A. L., Zaccara, S., Sullivan, K. D., Pandey, A., MacBeth, M. L., Inga, A., & Espinosa, J. M. (2017) · Genome Research · doi:10.1101/gr.220533.117 · Cited by 154 · see citing works

Rescue of non-sense mutated p53 tumor suppressor gene by aminoglycosides

Floquet, C., Deforges, J., Rousset, J., & Bidou, L. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq1277 · Cited by 153 · see citing works

COTI-2, a novel small molecule that is active against multiple human cancer cell linesin vitroandin vivo

Salim, K. Y., Vareki, S. M., Danter, W. R., San‐Marina, S., & Koropatnick, J. D. (2016) · Oncotarget · doi:10.18632/oncotarget.9133 · Cited by 152 · see citing works

Co-localization of mutant p53 and amyloid-like protein aggregates in breast tumors

Levy, C. B., Stumbo, A. C., Bom, A. P. D. A., Portari, E. A., Carneiro, Y., Silva, J. L., & Gallo, C. V. D. M. (2010) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2010.10.017 · Cited by 150 · see citing works

Effects of Common Cancer Mutations on Stability and DNA Binding of Full-length p53 Compared with Isolated Core Domains

Ang, H. C., Joerger, A. C., Mayer, S., & Fersht, A. R. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m604209200 · Cited by 146 · see citing works

Rescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide

Issaeva, N., Friedler, A., Bozko, P. M., Wiman, K. G., Fersht, A. R., & Selivanova, G. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1835733100 · Cited by 144 · see citing works

Stabilization of p53 by CP-31398 Inhibits Ubiquitination without Altering Phosphorylation at Serine 15 or 20 or MDM2 Binding

Wang, W., Takimoto, R., Rastinejad, F., & El‐Deiry, W. S. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.6.2171-2181.2003 · Cited by 144 · see citing works

Kinetic Instability of p53 Core Domain Mutants

Friedler, A., Veprintsev, D. B., Hansson, L. O., & Fersht, A. R. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m302458200 · Cited by 140 · see citing works

PRIMA-1Met/APR-246 Induces Apoptosis and Tumor Growth Delay in Small Cell Lung Cancer Expressing Mutant p53

Zandi, R., Selivanova, G., Christensen, C. L., Gerds, T. A., Willumsen, B. M., & Poulsen, H. S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3168 · Cited by 137 · see citing works

Erratum: APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase

Peng, X., Zhang, M., Conserva, F., Hosny, G., Selivanova, G., Bykov, V. J. N., Arnér, E. S. J., & Wiman, K. G. (2017) · Cell Death and Disease · doi:10.1038/cddis.2016.137 · Cited by 134 · see citing works

TXNIP maintains the hematopoietic cell pool by switching the function of p53 under oxidative stress

Jung, H., Kim, M. J., Kim, D. O., Kim, W. S., Yoon, S.-J., Park, Y.-J., Yoon, S. R., Kim, T.-D., Suh, H.-W., Yun, S., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.06.002 · Cited by 132 · see citing works

A temperature‐sensitive mutant of human p53.

Zhang, W., Guo, X. Y., Hu, G., Liu, W. B., Shay, J. W., & Deisseroth, A. B. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06543.x · Cited by 127 · see citing works

Proposed molecular and cellular mechanism for aminoglycoside ototoxicity

Hutchin, T. P., & Cortopassi, G. A. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.11.2517 · Cited by 124 · see citing works

Reciprocal Interference between the Sequence-Specific Core and Nonspecific C-Terminal DNA Binding Domains of p53: Implications for Regulation

Anderson, M. E., Woelker, B., Reed, M. J., Wang, P., & Tegtmeyer, P. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.11.6255 · Cited by 120 · see citing works

Wild-type p53 induces apoptosis in a Burkitt lymphoma (BL) line that carries mutant p53.

Ramqvist, T., Magnússon, K. P., Wang, Y., Székely, L., Klein, G., & Wiman, K. G. (1993) · PubMed · Cited by 120 · see citing works

Restoring p53 active conformation by zinc increases the response of mutant p53 tumor cells to anticancer drugs

Puca, R., Nardinocchi, L., Porru, M., Simon, A. J., Rechavi, G., Leonetti, C., Givol, D., & D’Orazi, G. (2011) · Cell Cycle · doi:10.4161/cc.10.10.15642 · Cited by 117 · see citing works

2-Sulfonylpyrimidines: Mild alkylating agents with anticancer activity toward p53-compromised cells

Bauer, M. R., Joerger, A. C., & Fersht, A. R. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1610421113 · Cited by 117 · see citing works

Mutant p53 targeting by the low molecular weight compound STIMA‐1

Zache, N., Lambert, J. M. R., Rökaeus, N., Shen, J., Hainaut, P. L., Bergman, J., Wiman, K. G., & Bykov, V. J. N. (2008) · Molecular Oncology · doi:10.1016/j.molonc.2008.02.004 · Cited by 116 · see citing works

Mutant p53: a novel target for the treatment of patients with triple‐negative breast cancer?

Synnott, N. C., Murray, A., McGowan, P. M., Kiely, M., Kiely, P. A., O’Donovan, N., O’Connor, D. P., Gallagher, W. M., Crown, J. P., & Duffy, M. J. (2016) · International Journal of Cancer · doi:10.1002/ijc.30425 · Cited by 112 · see citing works

Small molecule restoration of wildtype structure and function of mutant p53 using a novel zinc-metallochaperone based mechanism

Yu, X., Blanden, A. R., Narayanan, S., Jayakumar, L., Lubin, D. J., Augeri, D. J., Kimball, S. D., Loh, S. N., & Carpizo, D. R. (2014) · Oncotarget · doi:10.18632/oncotarget.2432 · Cited by 111 · see citing works

A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis

Weinmann, L., Wischhusen, J., Demma, M. J., Naumann, U., Roth, P., Dasmahapatra, B., & Weller, M. (2008) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4402301 · Cited by 107 · see citing works

SCH529074, a Small Molecule Activator of Mutant p53, Which Binds p53 DNA Binding Domain (DBD), Restores Growth-suppressive Function to Mutant p53 and Interrupts HDM2-mediated Ubiquitination of Wild Type p53

Demma, M. J., Maxwell, E., Ramos, R., Liang, L., Li, C., Hesk, D., Rossman, R. R., Mallams, A. K., Doll, R. J., Liu, M., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.083469 · Cited by 107 · see citing works

Mutant p53 reactivation by PRIMA-1MET induces multiple signaling pathways converging on apoptosis

Lambert, J. M. R., Moshfegh, A., Hainaut, P. L., Wiman, K. G., & Bykov, V. J. N. (2009) · Oncogene · doi:10.1038/onc.2009.425 · Cited by 106 · see citing works

Characterization of new-generation aminoglycoside promoting premature termination codon readthrough in cancer cells

Bidou, L., Bugaud, O., Белахов, В. В., Baasov, T., & Namy, O. (2017) · RNA Biology · doi:10.1080/15476286.2017.1285480 · Cited by 104 · see citing works

APR-246 potently inhibits tumour growth and overcomes chemoresistance in preclinical models of oesophageal adenocarcinoma

Liu, D. S. H., Read, M. D., Cullinane, C. M., Azar, W. J., Fennell, C. M., Montgomery, K. G., Haupt, S., Haupt, Y., Wiman, K. G., Duong, C. P., et al. (2015) · Gut · doi:10.1136/gutjnl-2015-309770 · Cited by 95 · see citing works

Regulation of Mutant p53 Temperature-sensitive DNA Binding

Friedlander, P. A., Legros, Y., Soussi, T., & Prives, C. L. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.41.25468 · Cited by 94 · see citing works

Involvement of Human Release Factors eRF3a and eRF3b in Translation Termination and Regulation of the Termination Complex Formation

Chauvin, C., Salhi, S., Le Goff, C., Viranaicken, W., Diop, D., & Jean-Jean, O. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.14.5801-5811.2005 · Cited by 90 · see citing works

Emodin enhances cisplatin-induced cytotoxicity in human bladder cancer cells through ROS elevation and MRP1 downregulation

Li, X., Wang, H., Wang, J., Chen, Y., Yin, X., Shi, G., Li, H., Hu, Z., & Liang, X. (2016) · BMC Cancer · doi:10.1186/s12885-016-2640-3 · Cited by 87 · see citing works

Synthetic Metallochaperone ZMC1 Rescues Mutant p53 Conformation by Transporting Zinc into Cells as an Ionophore

Blanden, A. R., Yu, X., Wolfe, A. J., Gilleran, J., Augeri, D. J., O’Dell, R. S., Olson, E. C., Kimball, S. D., Emge, T. J., Movileanu, L., et al. (2015) · Molecular Pharmacology · doi:10.1124/mol.114.097550 · Cited by 86 · see citing works

TP53 Genomic Status Regulates Sensitivity of Gastric Cancer Cells to the Histone Methylation Inhibitor 3-Deazaneplanocin A (DZNep)

Cheng, L. L., Itahana, Y., Lei, Z. D., Chia, N., Wu, Y., Yu, Y., Zhang, S. L., Thike, A. A., Pandey, A., Rozen, S., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0036 · Cited by 85 · see citing works

An open-label phase I dose-finding study of APR-246 in hematological malignancies

Deneberg, S., Cherif, H., Lazarevic, V, Andersson, P.-O., von Euler, M., Juliusson, G., & Lehmann, S. (2016) · Blood Cancer Journal · doi:10.1038/bcj.2016.60 · Cited by 84 · see citing works

Reactivating mutant p53 using small molecules as zinc metallochaperones: awakening a sleeping giant in cancer

Blanden, A. R., Yu, X., Loh, S. N., Levine, A. J., & Carpizo, D. R. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.07.006 · Cited by 83 · see citing works

Small-Molecule Reactivation of Mutant p53 to Wild-Type-like p53 through the p53-Hsp40 Regulatory Axis

Hiraki, M., Hwang, S.-Y., Cao, S., Ramadhar, T. R., Byun, S., Yoon, K. W., Lee, J. H., Chu, K., Gurkar, A. U., Kolev, V., et al. (2015) · Chemistry &amp; Biology · doi:10.1016/j.chembiol.2015.07.016 · Cited by 81 · see citing works

Novel small molecules potentiate premature termination codon readthrough by aminoglycosides

Baradaran‐Heravi, A., Balgi, A. D., Zimmerman, C., Choi, K., Shidmoossavee, F. S., Tan, J. S. C., bergeaud, C., Krause, A., Flibotte, S., Shimizu, Y., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw638 · Cited by 78 · see citing works

Cancer syndromes and therapy by stop-codon readthrough

Bordeira–Carriço, R., Pêgo, A. P., Santos, M. A. S., & Oliveíra, C. (2012) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2012.09.004 · Cited by 76 · see citing works

Cancer therapeutic approach based on conformational stabilization of mutant p53 protein by small peptides

Tal, P., Eizenberger, S., Cohen, E., Goldfinger, N., Pietrokovski, S., Oren, M., & Rotter, V. (2016) · Oncotarget · doi:10.18632/oncotarget.7857 · Cited by 74 · see citing works

Stabilization of mutant p53 via alkylation of cysteines and effects on DNA binding

Kaar, J. L., Basse, N., Joerger, A. C., Stephens, E., Rutherford, T. J., & Fersht, A. R. (2010) · Protein Science · doi:10.1002/pro.507 · Cited by 71 · see citing works

APR-246 exhibits anti-leukemic activity and synergism with conventional chemotherapeutic drugs in acute myeloid leukemia cells

Ali, D., Jönsson‐Videsäter, K., Deneberg, S., Bengtzén, S., Nahi, H., Paul, C., & Lehmann, S. (2010) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2010.01557.x · Cited by 70 · see citing works

Oncogenic Intra-p53 Family Member Interactions in Human Cancers

Ferraiuolo, M. A., Agostino, S. D., Blandino, G., & Strano, S. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00077 · Cited by 69 · see citing works

PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines

Izetti, P., Hautefeuille, A. H., Abujamra, A. L., de Farias, C. B., Giacomazzi, J., Alemar, B., Lenz, G., Roesler, R., Schwartsmann, G., Osvaldt, A. B., et al. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0090-9 · Cited by 68 · see citing works

PRIMA-1MET inhibits growth of mouse tumors carrying mutant p53.

(2008) · PubMed Central · doi:10.3233/clo-2008-0440 · Cited by 68 · see citing works

Design and synthesis of a C7-aryl piperlongumine derivative with potent antimicrotubule and mutant p53-reactivating properties

Punganuru, S. R., Madala, H. R., Venugopal, S. N., Samala, R., Mikelis, C. M., & Srivenugopal, K. S. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.10.052 · Cited by 67 · see citing works

Thiosemicarbazones Functioning as Zinc Metallochaperones to Reactivate Mutant p53

Yu, X., Blanden, A. R., Tsang, A. T., Zaman, S., Liu, Y., Gilleran, J., Bencivenga, A. F., Kimball, S. D., Loh, S. N., & Carpizo, D. R. (2017) · Molecular Pharmacology · doi:10.1124/mol.116.107409 · Cited by 66 · see citing works

More targets, more pathways and more clues for mutant p53

Garritano, S., Inga, A., Gemignani, F., & Landi, S. (2013) · Oncogenesis · doi:10.1038/oncsis.2013.15 · Cited by 63 · see citing works

Ataluren in cystic fibrosis: development, clinical studies and where are we now?

Abidin, N. Z., Haq, I. J., Gardner, A. I., & Brodlie, M. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1359255 · Cited by 63 · see citing works

APR-246 (PRIMA-1 MET ) strongly synergizes with AZD2281 (olaparib) induced PARP inhibition to induce apoptosis in non-small cell lung cancer cell lines

Deben, C., Lardon, F., Wouters, A., de Beeck, K. O., den Bossche, J. V., Jacobs, J., Steen, N. V. D., Peeters, M., Rolfo, C. D., Deschoolmeester, V., et al. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.03.017 · Cited by 60 · see citing works

p53 Reactivation by PRIMA-1Met (APR-246) sensitises V600E/KBRAF melanoma to vemurafenib

Krayem, M., Journé, F., Wiedig, M., Morandini, R., Najem, A., Salès, F., van Kempen, L. C. L. T., Sibille, C., Awada, A. H., Marine, J., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.12.002 · Cited by 58 · see citing works

PRIMA-1Met/APR-246 induces wild-type p53-dependent suppression of malignant melanoma tumor growth in 3D culture and in vivo

Bao, W., Chen, M., Zhao, X., Kumar, R., Spinnler, C., Thullberg, M., Issaeva, N., Selivanova, G., & Strömblad, S. (2011) · Cell Cycle · doi:10.4161/cc.10.2.14538 · Cited by 56 · see citing works

Anti‐leukaemic effects induced by APR‐246 are dependent on induction of oxidative stress and the NFE2L2/HMOX1 axis that can be targeted by PI3K and mTOR inhibitors in acute myeloid leukaemia cells

Ali, D., Mohammad, D. K., Mujahed, H., Jonson‐Videsäter, K., Nore, B., Paul, C., & Lehmann, S. (2016) · British Journal of Haematology · doi:10.1111/bjh.14036 · Cited by 49 · see citing works

Acute cytotoxicity of MIRA-1/NSC19630, a mutant p53-reactivating small molecule, against human normal and cancer cells via a caspase-9-dependent apoptosis

Bou‐Hanna, C., Jarry, A., Lodé, L., Schmitz, I., Schulze‐Osthoff, K., Küry, S., Bezieau, S., Mosnier, J., & LABOISSE, C. L. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.01.014 · Cited by 48 · see citing works

Variability in functional p53 reactivation by PRIMA-1Met/APR-246 in Ewing sarcoma

Aryee, D. N. T., Niedan, S., Bán, J., Schwentner, R., Muehlbacher, K., Kauer, M. O., Kofler, R., & Kovar, H. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.635 · Cited by 44 · see citing works

Small molecule MIRA-1 induces in vitro and in vivo anti-myeloma activity and synergizes with current anti-myeloma agents

Saha, M. N., Chen, Y., Chen, M.-H., Chen, G., & Chang, H. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.164 · Cited by 43 · see citing works

When a ribosome encounters a premature termination codon

Hwang, J., & Kim, Y. K. (2013) · BMB Reports · doi:10.5483/bmbrep.2013.46.1.002 · Cited by 43 · see citing works

Restoration of Mutant TP53 to Normal TP53 Function by Glycerol as a Chemical Chaperone

Ohnishi, T., Ohnishi, K., Wang, X., Takahashi, A., & Okaichi, K. (1999) · Radiation Research · doi:10.2307/3579838 · Cited by 39 · see citing works

PRIMA-1MET induces death in soft-tissue sarcomas cell independent of p53

Grellety, T., Laroche‐Clary, A., Chaire, V., Lagarde, P., Chibon, F., Neuville, A., & Italiano, A. (2015) · BMC Cancer · doi:10.1186/s12885-015-1667-1 · Cited by 32 · see citing works

Targeting mutant p53 protein and the tumor vasculature: an effective combination therapy for advanced breast tumors

Liang, Y., Besch-Williford, C. L., Benakanakere, I., Thorpe, P. E., & Hyder, S. M. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0851-x · Cited by 29 · see citing works

p53-stabilizing Agent CP-31398 Prevents Growth and Invasion of Urothelial Cancer of the Bladder in Transgenic UPII-SV40T Mice

Madka, V., Zhang, Y., Li, Q., Mohammed, A., Sindhwani, P., Lightfoot, S. A., Wu, X.-R., Kopelovich, L., & Rao, C. V. (2013) · Neoplasia · doi:10.1593/neo.13704 · Cited by 28 · see citing works

PRIMA-1Met induces apoptosis in Waldenström's Macroglobulinemia cells independent of p53

Sobhani, M., Abdi, J., Saha, M. N., Chen, C., & Chang, H. (2015) · Cancer Biology & Therapy · doi:10.1080/15384047.2015.1026482 · Cited by 28 · see citing works

PRIMA-1, a Mutant p53 Reactivator, Restores the Sensitivity of TP53 Mutant-Type Thyroid Cancer Cells to the Histone Methylation Inhibitor 3-Deazaneplanocin A

Cui, B., Yang, Q., Guan, H., Shi, B., Hou, P., & Ji, M. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3147 · Cited by 28 · see citing works

COTI-2, a new anticancer drug currently under clinical investigation, targets mutant p53 and negatively modulates the PI3K/AKT/mTOR pathway

Salim, K., Vareki, S. M., Danter, W. R., & Koropatnick, J. D. (2016) · European Journal of Cancer · doi:10.1016/s0959-8049(16)32638-7 · Cited by 24 · see citing works

Restoration by glycerol of p53-dependent apoptosis in cells bearing the mutant p53 gene

Ohnishi, H. (1999) · International Journal of Radiation Biology · doi:10.1080/095530099139557 · Cited by 22 · see citing works

PRIMA-1Met suppresses colorectal cancer independent of p53 by targeting MEK

Lu, T., Zou, Y., Xu, G., Potter, J. A., Taylor, G. L., Duan, Q., Yang, Q., Xiong, H., Qiu, H., Ye, D., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12940 · Cited by 22 · see citing works

All-codon scanning identifies p53 cancer rescue mutations

Baronio, R., Danziger, S. A., Hall, L., Salmon, K. A., Hatfield, G. W., Lathrop, R. H., & Kaiser, P. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq571 · Cited by 20 · see citing works

PISARRO: A EUTROC phase Ib study of APR-246 in combination with carboplatin (C) and pegylated liposomal doxorubicin (PLD) in platinum sensitive relapsed high grade serous ovarian cancer (HGSOC).

Gourley, C., Green, J., Gabra, H., Vergote, I. B., Basu, B., Brenton, J. D., Björklund, U., Smith, A., & von Euler, M. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.5571 · Cited by 19 · see citing works

Identification and structure–activity relationship studies of 3-methylene-2-norbornanone as potent anti-proliferative agents presumably working through p53 mediated apoptosis

Reddy, N. L., Hill, J. R., Ye, L., FERNANDES, P. B., & Stout, D. M. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.08.048 · Cited by 13 · see citing works

Broadening horizons: the role of ferroptosis in cancer

Chen, X., Kang, R., Kroemer, G., & Tang, D. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00462-0 · Cited by 2,942 · see citing works

Targeting apoptosis in cancer therapy

Carneiro, B. A., & El‐Deiry, W. S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0341-y · Cited by 2,594 · see citing works

Targeting Ferroptosis as a Vulnerability in Cancer

Lei, G., Zhuang, L., & Gan, B. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00459-0 · Cited by 2,252 · see citing works

Ferroptosis, necroptosis, and pyroptosis in anticancer immunity

Tang, R., Xu, J., Zhang, B., Liu, J., Liang, C., Hua, J., Meng, Q., Yu, X., & Shi, S. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00946-7 · Cited by 1,282 · see citing works

Targeting p53 pathways: mechanisms, structures, and advances in therapy

Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016 · see citing works

Mutant p53 as a guardian of the cancer cell

Mantovani, F., Collavin, L., & Sal, G. D. (2018) · Cell Death and Differentiation · doi:10.1038/s41418-018-0246-9 · Cited by 779 · see citing works

The role of ubiquitination in tumorigenesis and targeted drug discovery

Deng, L., Meng, T., Chen, L., Wei, W., & Wang, P. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0107-0 · Cited by 744 · see citing works

Targeting mutant p53 for cancer therapy: direct and indirect strategies

Hu, J., Cao, J., Topatana, W., Juengpanich, S., Li, S., Zhang, B., Shen, J., Cai, L., Cai, X., & Chen, M. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01169-0 · Cited by 557 · see citing works

Clinical update on head and neck cancer: molecular biology and ongoing challenges

Alsahafi, E., Begg, K., Amelio, I., Raulf, N., Lucarelli, P., Sauter, T., & Tavassoli, M. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1769-9 · Cited by 531 · see citing works

Overcoming cancer therapeutic bottleneck by drug repurposing

Zhang, Z., Zhou, L., Xie, N., Nice, E. C., Zhang, T., Cui, Y., & Huang, C. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00213-8 · Cited by 521 · see citing works

Mutant p53 in cancer: from molecular mechanism to therapeutic modulation

Chen, X., Zhang, T., Su, W., Dou, Z., Zhao, D., Jin, X., Lei, H., Wang, J., Xie, X., Cheng, B., et al. (2022) · Cell Death &amp; Disease · doi:10.1038/s41419-022-05408-1 · Cited by 494 · see citing works

Identifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid Tumors

Leko, V., & Rosenberg, S. A. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.07.013 · Cited by 449 · see citing works

Drug repurposing for cancer therapy

Xia, Y., Sun, M., Huang, H., & Jin, W.-L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01808-1 · Cited by 443 · see citing works

p53 modifications: exquisite decorations of the powerful guardian

Liu, Y., Tavana, O., & Gu, W. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz060 · Cited by 392 · see citing works

Sex differences in cancer mechanisms

Rubin, J. B., Lagas, J. S., Broestl, L., Sponagel, J., Rockwell, N., Rhee, G., Rosen, S. F., Chen, S., Klein, R. S., Imoukhuede, P. I., et al. (2020) · Biology of Sex Differences · doi:10.1186/s13293-020-00291-x · Cited by 370 · see citing works

Targeting p53 for the treatment of cancer

Duffy, M. J., Synnott, N. C., O’Grady, S., & Crown, J. P. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.07.005 · Cited by 351 · see citing works

The Role of p53 Signaling in Colorectal Cancer

Liebl, M. C., & Hofmann, T. G. (2021) · Cancers · doi:10.3390/cancers13092125 · Cited by 332 · see citing works

Towards precision medicine for AML

Döhner, H., Wei, A. H., & Löwenberg, B. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00509-w · Cited by 314 · see citing works

Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma

Qian, Y., Gong, Y., Fan, Z., Luo, G., Huang, Q., Deng, S., Cheng, H., Jin, K., Ni, Q., Yu, X., et al. (2020) · Journal of Hematology &amp; Oncology · doi:10.1186/s13045-020-00958-3 · Cited by 312 · see citing works

Targeting signaling pathways in prostate cancer: mechanisms and clinical trials

He, Y., Xu, W., Xiao, Y., Huang, H., Gu, D., & Ren, S. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01042-7 · Cited by 275 · see citing works

The complexity of p53-mediated metabolic regulation in tumor suppression

Liu, Y., & Gu, W. J. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.010 · Cited by 260 · see citing works

APR-246 reactivates mutant p53 by targeting cysteines 124 and 277

Zhang, Q., Bykov, V. J. N., Wiman, K. G., & Zawacka-Pankau, J. (2018) · Cell Death &amp; Disease · doi:10.1038/s41419-018-0463-7 · Cited by 261 · see citing works

Targeted therapy for head and neck cancer: signaling pathways and clinical studies

Li, Q., Tie, Y., Alu, A., Ma, X., & Shi, H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01297-0 · Cited by 269 · see citing works

Mutant p53 in cancer therapy—the barrier or the path

Zhou, X. Y., Hao, Q., & Lu, H. (2018) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjy072 · Cited by 244 · see citing works

Targeting mutations in cancer

Waarts, M. R., Stonestrom, A. J., Park, Y. C., & Levine, R. L. (2022) · Journal of Clinical Investigation · doi:10.1172/jci154943 · Cited by 236 · see citing works

Glutathione S-Transferases in Cancer

Singh, R. R., & Reindl, K. M. (2021) · Antioxidants · doi:10.3390/antiox10050701 · Cited by 239 · see citing works

Long noncoding RNA AGPG regulates PFKFB3-mediated tumor glycolytic reprogramming

Liu, J., Liu, Z., Wu, Q.-N., Lu, Y., Wong, C., Miao, L., Wang, Y., Wang, Z., Jin, Y., He, M.-M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15112-3 · Cited by 226 · see citing works

Mutant p53 in Cancer Progression and Targeted Therapies

Zhu, G., Pan, C., Bei, J., Li, B., Chen, L., Xu, Y., & Fu, X. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.595187 · Cited by 220 · see citing works

Injectable thermosensitive hydrogel-based drug delivery system for local cancer therapy

Xiao, Y., Gu, Y., Qin, L., Chen, L., Chen, X., Cui, W., Li, F., Xiang, N., & He, X. (2021) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2021.111581 · Cited by 216 · see citing works

Acetylation of MORC2 by NAT10 regulates cell-cycle checkpoint control and resistance to DNA-damaging chemotherapy and radiotherapy in breast cancer

Liu, H., Liu, Y., Yang, F., Zhang, L., Zhang, F., Hu, X., Shao, Z., & Li, D. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa130 · Cited by 205 · see citing works

Wild-Type p53 Promotes Cancer Metabolic Switch by Inducing PUMA-Dependent Suppression of Oxidative Phosphorylation

Kim, J., Yu, L., Chen, W., Xu, Y., Wu, M., Todorova, D., Tang, Q., Feng, B., Jiang, L., Chen, G., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2018.12.012 · Cited by 202 · see citing works

Ferroptosis as a mechanism to mediate p53 function in tumor radiosensitivity

Lei, G., Zhang, Y., Hong, T., Zhang, X., Liu, X., Mao, C., Yan, Y., Koppula, P., Cheng, W., Sood, A. K., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01790-w · Cited by 201 · see citing works

Trial watch: IDO inhibitors in cancer therapy

Naour, J. L., Galluzzi, L., Zitvogel, L., Kroemer, G., & Vacchelli, E. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1777625 · Cited by 188 · see citing works

The anti-cancer effects and mechanisms of lactic acid bacteria exopolysaccharides in vitro: A review

Wu, J., Zhang, Y., Ye, L., & Wang, C. (2020) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2020.117308 · Cited by 175 · see citing works

Injectable Hydrogels for Localized Cancer Therapy

Fan, D., Tian, Y., & Liu, Z. (2019) · Frontiers in Chemistry · doi:10.3389/fchem.2019.00675 · Cited by 167 · see citing works

The role of ubiquitin-specific peptidases in cancer progression

Young, M.-J., Hsu, K., Lin, T. E., Chang, W., & Hung, J. (2019) · Journal of Biomedical Science · doi:10.1186/s12929-019-0522-0 · Cited by 161 · see citing works

Reactive Oxygen Species Induced p53 Activation: DNA Damage, Redox Signaling, or Both?

Shi, T., & Dansen, T. B. (2020) · Antioxidants and Redox Signaling · doi:10.1089/ars.2020.8074 · Cited by 164 · see citing works

Gain-of-Function Mutant p53: All the Roads Lead to Tumorigenesis

Stein, Y., Rotter, V., & Aloni-Grinstein, R. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20246197 · Cited by 161 · see citing works

p53 at the crossroad of DNA replication and ribosome biogenesis stress pathways

Lindström, M. S., Bártek, J., & Maya‐Mendoza, A. (2022) · Cell Death and Differentiation · doi:10.1038/s41418-022-00999-w · Cited by 161 · see citing works

Thermocatalytic hydrogen peroxide generation and environmental disinfection by Bi2Te3 nanoplates

Lin, Y.-J., Khan, I., Saha, S., Wu, C., Barman, S. R., Kao, F., & Lin, Z. (2021) · Nature Communications · doi:10.1038/s41467-020-20445-0 · Cited by 161 · see citing works

The Mevalonate Pathway, a Metabolic Target in Cancer Therapy

Guerra, B., Recio, C., Aranda-Tavío, H., Guerra-Rodríguez, M., García-Castellano, J. M., & Fernández‐Pérez, L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.626971 · Cited by 160 · see citing works

Classification of adult‐type diffuse gliomas: Impact of the World Health Organization 2021 update

Whitfield, B. T., & Huse, J. T. (2022) · Brain Pathology · doi:10.1111/bpa.13062 · Cited by 162 · see citing works

Current developments of targeting the p53 signaling pathway for cancer treatment

Huang, J. L. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107720 · Cited by 155 · see citing works

Hypoxia-induced circWSB1 promotes breast cancer progression through destabilizing p53 by interacting with USP10

Yang, R., Chen, H., Xing, L., Wang, B., Hu, M., Ou, X., Chen, H., Deng, Y., Liu, D., Jiang, R., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01567-z · Cited by 154 · see citing works

Mutant p53 on the Path to Metastasis

Tang, Q., Su, Z., Gu, W., & Rustgi, A. K. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.11.004 · Cited by 152 · see citing works

Glutathione metabolism in ferroptosis and cancer therapy

Xue, X., Wang, M., Cui, J., Yang, M., Ma, L., Kang, R., Tang, D., & Wang, J. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217697 · Cited by 154 · see citing works

Targeting apoptotic pathways for cancer therapy

Tian, X., Srinivasan, P. R., Tajiknia, V., Uruchurtu, A. F. S. S., Seyhan, A. A., Carneiro, B. A., Cruz, A. D. L., Pinho-Schwermann, M. P., George, A., Zhao, S., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci179570 · Cited by 150 · see citing works

T-cell Acute Lymphoblastic Leukemia: A Roadmap to Targeted Therapies

Cordo’, V., van der Zwet, J. C. G., Canté-Barrett, K., Pieters, R., & Meijerink, J. P. P. (2020) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-20-0093 · Cited by 143 · see citing works

How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance

Stiewe, T., & Haran, T. E. (2018) · Drug Resistance Updates · doi:10.1016/j.drup.2018.05.001 · Cited by 139 · see citing works

TP53 in bone and soft tissue sarcomas

Thoenen, E. A., Curl, A., & Iwakuma, T. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.06.010 · Cited by 137 · see citing works

Mutation Hotspots in the β-Catenin Gene: Lessons from the Human Cancer Genome Databases.

Kim, S., & Jeong-Yu, S. (2019) · Europe PMC (PubMed Central) · doi:10.14348/molcells.2018.0436 · Cited by 134 · see citing works

p53 as a hub in cellular redox regulation and therapeutic target in cancer

Eriksson, S. E., Ceder, S., Bykov, V. J. N., & Wiman, K. G. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz005 · Cited by 123 · see citing works

Protein mimetic amyloid inhibitor potently abrogates cancer-associated mutant p53 aggregation and restores tumor suppressor function

Palanikumar, L., Karpauskaite, L., Al‐Sayegh, M., Chehade, I., Alam, M., Hassan, S., Maity, D., Ali, L., Kalmouni, M., Hunashal, Y., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23985-1 · Cited by 123 · see citing works

Ubiquitination by HUWE1 in tumorigenesis and beyond

Kao, S.-H., Wu, H., & Wu, K. (2018) · Journal of Biomedical Science · doi:10.1186/s12929-018-0470-0 · Cited by 122 · see citing works

Pathogenesis and Current Treatment of Osteosarcoma: Perspectives for Future Therapies

Rathore, R., & Tine, B. A. V. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10061182 · Cited by 122 · see citing works

Optical/electrochemical methods for detecting mitochondrial energy metabolism

Ji, W., Tang, X. X., Du, W., Lu, Y., Wang, N., Wu, Q., Wei, W., Liu, J., Yu, H., Ma, B., et al. (2021) · Chemical Society Reviews · doi:10.1039/d0cs01610a · Cited by 124 · see citing works

Development of synthetic lethality in cancer: molecular and cellular classification

Li, S., Topatana, W., Juengpanich, S., Cao, J., Hu, J., Zhang, B., Ma, D., Cai, X., & Chen, M. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00358-6 · Cited by 117 · see citing works

Overcoming anti-cancer drug resistance via restoration of tumor suppressor gene function

Gao, L., Wu, Z., Assaraf, Y. G., Chen, Z., & Wang, L. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100770 · Cited by 118 · see citing works

Role of p53 in the Regulation of the Inflammatory Tumor Microenvironment and Tumor Suppression

Uehara, I., & Tanaka, N. (2018) · Cancers · doi:10.3390/cancers10070219 · Cited by 115 · see citing works

Mesoporous cerium oxide-coated upconversion nanoparticles for tumor-responsive chemo-photodynamic therapy and bioimaging

Jia, T., Xu, J., Dong, S., He, F., Zhong, C., Yang, G., Bi, H., Xu, M., Hu, Y., Yang, D., et al. (2019) · Chemical Science · doi:10.1039/c9sc01615e · Cited by 115 · see citing works

Structures of p53/BCL-2 complex suggest a mechanism for p53 to antagonize BCL-2 activity

Wei, H., Wang, H., Wang, G., Qu, L., Jiang, L., Dai, S., Chen, X., Zhang, Y., Chen, Z., Li, Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40087-2 · Cited by 119 · see citing works

Regulators of Oncogenic Mutant TP53 Gain of Function

Yamamoto, S., & Iwakuma, T. (2018) · Cancers · doi:10.3390/cancers11010004 · Cited by 111 · see citing works

Natural products targeting the p53-MDM2 pathway and mutant p53: Recent advances and implications in cancer medicine

Qin, J., Li, X., Hunt, C., Wang, W., Wang, H., & Zhang, R. (2018) · Genes & Diseases · doi:10.1016/j.gendis.2018.07.002 · Cited by 111 · see citing works

Mechanistic basis for impaired ferroptosis in cells expressing the African-centric S47 variant of p53

Leu, J. I.-J., Murphy, M. E., & George, D. L. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1821277116 · Cited by 112 · see citing works

Application of Approved Cisplatin Derivatives in Combination Therapy against Different Cancer Diseases

Tsvetkova, D. D., & Ivanova, S. A. (2022) · Molecules · doi:10.3390/molecules27082466 · Cited by 112 · see citing works

p53 haploinsufficiency and increased mTOR signalling define a subset of aggressive hepatocellular carcinoma

Luo, Y., Fang, L., Yu, H., Zhang, J., Lin, X., Liu, X., Wu, D., Li, G.-X., Deng, H., Zhang, Y., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.07.036 · Cited by 105 · see citing works

Insights of Crosstalk between p53 Protein and the MKK3/MKK6/p38 MAPK Signaling Pathway in Cancer

Stramucci, L., Pranteda, A., & Bossi, G. (2018) · Cancers · doi:10.3390/cancers10050131 · Cited by 104 · see citing works

Eprenetapopt triggers ferroptosis, inhibits NFS1 cysteine desulfurase, and synergizes with serine and glycine dietary restriction

Fujihara, K. M., Zhang, B. Z., Jackson, T. D., Ogunkola, M. O., Nijagal, B., Milne, J. V., Sallman, D. A., Ang, C.-S., Nikolic, I., Kearney, C. J., et al. (2022) · Science Advances · doi:10.1126/sciadv.abm9427 · Cited by 103 · see citing works

Flubendazole, FDA-approved anthelmintic, elicits valid antitumor effects by targeting P53 and promoting ferroptosis in castration-resistant prostate cancer

Zhou, X., Zou, L., Chen, W., Yang, T., Luo, J., Wu, K., Shu, F., Tan, X., Yu, Y., Cen, S., et al. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105305 · Cited by 99 · see citing works

Cell-Selective Messenger RNA Delivery and CRISPR/Cas9 Genome Editing by Modulating the Interface of Phenylboronic Acid-Derived Lipid Nanoparticles and Cellular Surface Sialic Acid

Tang, Q., Liu, J., Jiang, Y. Y., Zhang, M., Mao, L., & Wang, M. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b17749 · Cited by 98 · see citing works

Targeting the Oncogenic p53 Mutants in Colorectal Cancer and Other Solid Tumors

Li, H., Zhang, J., TONG, J. H. M., Chan, A. W. H., Yu, J. Q., Kang, W., & To, K. F. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20235999 · Cited by 96 · see citing works

Cell fate regulation governed by p53: Friends or reversible foes in cancer therapy

Song, B., Yang, P., & Zhang, S. (2024) · 癌症：英文版 · doi:10.1002/cac2.12520 · Cited by 97 · see citing works

Mutant p53 drives cancer chemotherapy resistance due to loss of function on activating transcription of PUMA

Huang, Y., Liu, N., Liu, J., Liu, Y., Zhang, C., Long, S., Luo, G., Zhang, L., & Zhang, Y. (2019) · Cell Cycle · doi:10.1080/15384101.2019.1688951 · Cited by 94 · see citing works

Identification of a highly lethal V3 + TP53 + subset in ALK + lung adenocarcinoma

Christopoulos, P., Kirchner, M., Bozorgmehr, F., Endris, V., Elsayed, M., Budczies, J., Ristau, J., Penzel, R., Herth, F. J. F., Heußel, C. P., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31893 · Cited by 93 · see citing works

Deep learning-based classification and mutation prediction from histopathological images of hepatocellular carcinoma

Liao, H., Long, Y., Han, R., Wang, W., Xu, L., Liao, M., Zhang, Z., Wu, Z., Shang, X., Li, X., et al. (2020) · Clinical and Translational Medicine · doi:10.1002/ctm2.102 · Cited by 92 · see citing works

Emerging next-generation sequencing-based discoveries for targeted osteosarcoma therapy

Zhao, J., Dean, D. C., Hornicek, F. J., Yu, X., & Duan, Z. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.01.020 · Cited by 90 · see citing works

Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute Leukemia

Stein, E. M., DeAngelo, D. J., Chromik, J., Chatterjee, M., Bauer, S., Lin, C.-C., Suárez, C., Vos, F. D., Steeghs, N., Cassier, P. A., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1295 · Cited by 88 · see citing works

p53 reactivation with induction of massive apoptosis-1 (PRIMA-1) inhibits amyloid aggregation of mutant p53 in cancer cells

Rangel, L. P., Ferretti, G. D. S., Costa, C. L., Andrade, S. M. M. V., Carvalho, R. S., da Costa, D. C. F., & Silva, J. L. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.004671 · Cited by 89 · see citing works

p53 Promoted Ferroptosis in Ovarian Cancer Cells Treated with Human Serum Incubated-Superparamagnetic Iron Oxides

Zhang, Y., Xia, M., Zhou, Z., Hu, X., Wang, J., Zhang, M., Li, Y., Sun, L., Chen, F., & Yu, H. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s282489 · Cited by 90 · see citing works

Complex karyotype in de novo acute myeloid leukemia: typical and atypical subtypes differ molecularly and clinically

Mrózek, K., Eisfeld, A., Kohlschmidt, J., Carroll, A. J., Walker, C. J., Nicolet, D., Blachly, J. S., Bill, M., Papaioannou, D., Wang, E. S., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0390-3 · Cited by 88 · see citing works

Drugging “undruggable” genes for cancer treatment: Are we making progress?

Duffy, M. J., & Crown, J. P. (2020) · International Journal of Cancer · doi:10.1002/ijc.33197 · Cited by 85 · see citing works

Emerging Pathological Engagement of Ferroptosis in Gut Diseases

Gao, W., Zhang, T., & Wu, H. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/4246255 · Cited by 88 · see citing works

DAXX represents a new type of protein-folding enabler

Huang, L., Agrawal, T., Zhu, G., Yu, S., Tao, L., Lin, J., Marmorstein, R., Shorter, J., & Yang, X. (2021) · Nature · doi:10.1038/s41586-021-03824-5 · Cited by 83 · see citing works

Targeting oxidative stress-mediated regulated cell death as a vulnerability in cancer

Chen, D., Guo, Z., Yao, L., Sun, Y., Dian, Y., Zhao, D., Ke, Y., Zeng, F., Zhang, C., Deng, G., et al. (2025) · Redox Biology · doi:10.1016/j.redox.2025.103686 · Cited by 88 · see citing works

N6-methyladenosine mediates arsenite-induced human keratinocyte transformation by suppressing p53 activation

Zhao, T., Sun, D., Zhao, M., Lai, Y., Liu, Y., & Zhang, Z. (2020) · Environmental Pollution · doi:10.1016/j.envpol.2019.113908 · Cited by 85 · see citing works

Deep CRISPR mutagenesis characterizes the functional diversity of TP53 mutations

Funk, J. S., Klimovich, M., Drangenstein, D., Pielhoop, O., Hunold, P., Borowek, A., Noeparast, M., Pavlakis, E., Neumann, M. M., Balourdas, D.-I., et al. (2025) · Nature Genetics · doi:10.1038/s41588-024-02039-4 · Cited by 92 · see citing works

Pharmacological reactivation of p53 in the era of precision anticancer medicine

Tuval, A., Strandgren, C., Heldin, A., Palomar-Siles, M., & Wiman, K. G. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00842-2 · Cited by 84 · see citing works

Therapeutic vaccines for breast cancer: Has the time finally come?

Corti, C., Giachetti, P. P. M. B., Eggermont, A. M. M., Delaloge, S., & Curigliano, G. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.10.027 · Cited by 84 · see citing works

Deregulation and Targeting of TP53 Pathway in Multiple Myeloma

Jovanović, K., Escure, G., Demonchy, J., Willaume, A., de Wyngaert, Z. V., Farhat, M.-M., Chauvet, P., Facon, T. T. F., Quesnel, B., & Manier, S. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2018.00665 · Cited by 82 · see citing works

Germline risk of clonal haematopoiesis

Silver, A. J., Bick, A. G., & Savona, M. R. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-021-00356-6 · Cited by 80 · see citing works

Structural basis of reactivation of oncogenic p53 mutants by a small molecule: methylene quinuclidinone (MQ)

Degtjarik, O., Golovenko, D., Diskin-Posner, Y., Abrahmsén, L., Rozenberg, H., & Shakked, Z. (2021) · Nature Communications · doi:10.1038/s41467-021-27142-6 · Cited by 78 · see citing works

COTI-2 reactivates mutant p53 and inhibits growth of triple-negative breast cancer cells

Synnott, N. C., O’Connell, D. J., Crown, J. P., & Duffy, M. J. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05435-1 · Cited by 82 · see citing works

Nanoparticle-mediated TRPV1 channel blockade amplifies cancer thermo-immunotherapy via heat shock factor 1 modulation

Li, T., Jiang, S., Zhang, Y., Luo, J., Li, M., Ke, H., Deng, Y., Yang, T., Sun, X., & Chen, H. (2023) · Nature Communications · doi:10.1038/s41467-023-38128-x · Cited by 81 · see citing works

Venetoclax therapy and emerging resistance mechanisms in acute myeloid leukaemia

Nwosu, G. O., Ross, D. M., Powell, J. A., & Pitson, S. M. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06810-7 · Cited by 80 · see citing works

USP15-dependent lysosomal pathway controls p53-R175H turnover in ovarian cancer cells

Padmanabhan, A., Candelaria, N., Wong, K.-K., Nikolai, B. C., Lonard, D. M., O’Malley, B. W., & Richards, J. S. (2018) · Nature Communications · doi:10.1038/s41467-018-03599-w · Cited by 88 · see citing works

Analysis and Interpretation of the Impact of Missense Variants in Cancer

Petrosino, M., Novak, L., Pasquo, A., Chiaraluce, R., Turina, P., Capriotti, E., & Consalvi, V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115416 · Cited by 81 · see citing works

Targeting Ribosome Biogenesis in Cancer: Lessons Learned and Way Forward

Zisi, A., Bártek, J., & Lindström, M. S. (2022) · Cancers · doi:10.3390/cancers14092126 · Cited by 80 · see citing works

Human MYC G-quadruplex: From discovery to a cancer therapeutic target

Wang, W., Hu, S., Gu, Y., Yan, Y., Stovall, D. B., Li, D., & Sui, G. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188410 · Cited by 76 · see citing works

The multiple roles and therapeutic potential of HSP60 in cancer

Tang, Y., Zhou, Y., Fan, S., & Wen, Q. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115096 · Cited by 78 · see citing works

TP53 Mutation as Potential Negative Predictor for Response of Anti-CTLA-4 Therapy in Metastatic Melanoma

Xiao, W., Du, N., Huang, T., Guo, J., Mo, X., Yuan, T., Chen, Y., Ye, T., Xu, C., Wang, W., et al. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.05.019 · Cited by 75 · see citing works

Pharmacological targeting of mutant p53

Kogan, S., & Carpizo, D. R. (2016) · Translational Cancer Research · doi:10.21037/tcr.2016.11.74 · Cited by 24 · see citing works

Strategies for therapeutic targeting of the p53 pathway in cancer

Wiman, K. G. (2006) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401921 · Cited by 135 · see citing works

Pharmacological reactivation of p53 as a strategy to treat cancer

Zawacka‐Pankau, J., & Selivanova, G. (2015) · Journal of Internal Medicine · doi:10.1111/joim.12336 · Cited by 82 · see citing works

Pharmacological reactivation of p53 in the era of precision anticancer medicine

Tuval, A., Strandgren, C., Heldin, A., Palomar-Siles, M., & Wiman, K. G. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00842-2 · Cited by 84 · see citing works

Pharmacological reactivation of mutant p53: from protein structure to the cancer patient

Wiman, K. G. (2010) · Oncogene · doi:10.1038/onc.2010.188 · Cited by 140 · see citing works